Tiziana Life Sciences Ltd (TLSA NASDAQ) stock market data APIs
$1.3545
-0.06(-4.4%)
as of February 6, 2026
Try our APIs with
free plan!
Tiziana Life Sciences Ltd Financial Data Overview
Price chart is built with
Anychart
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Prev. Close
1.3545
Open
1.2902
High
1.3845
Low
1.2813
52 wk Range
0.6612-2.6
Market Cap
173 M
Shares Outstanding
127 M
Revenue
-3 595 000
EPS
-0.05
Beta
0.248
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tiziana Life Sciences Ltd data using free add-ons & libraries
Get Tiziana Life Sciences Ltd Fundamental Data
Tiziana Life Sciences Ltd Fundamental data includes:
- Net Revenue: -3 595 000
- EBITDA: -18 464 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-03
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tiziana Life Sciences Ltd News
New
Tiziana's Intranasal Foralumab Study Results Published In Peer-Reviewed Journal
(RTTNews) - Tiziana Life Sciences, Ltd. (TLSA) announced that its open-label clinical study of intranasal foralumab in non-active secondary progressive multiple sclerosis has now been peer-reviewed an...
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, ant...
Tiziana Life Sciences prices $8M registered direct offering
* Tiziana Life Sciences (TLSA [https://seekingalpha.com/symbol/TLSA]) priced [https://seekingalpha.com/pr/20367108-tiziana-life-sciences-announces-registered-direct-offering-of-up-to-approximately-1...
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance
(RTTNews) - Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting strong gains on the back of corporate update...
Get Tiziana Life Sciences Ltd fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
